Hepatitis A - Pipeline Review, H2 2020
Hepatitis A - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2020, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.
Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Unknown stages are 4, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2020, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.
Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Unknown stages are 4, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A - Overview
Hepatitis A - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis A - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis A - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
China National Pharmaceutical Group Corp
Etna Biotech Srl
Indian Immunologicals Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Novo Medi Sciences Pvt Ltd
Sinovac Biotech Ltd
Hepatitis A - Drug Profiles
BR-8003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A + hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A [strain (RGSB)] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis A - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A - Overview
Hepatitis A - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis A - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis A - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
China National Pharmaceutical Group Corp
Etna Biotech Srl
Indian Immunologicals Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Novo Medi Sciences Pvt Ltd
Sinovac Biotech Ltd
Hepatitis A - Drug Profiles
BR-8003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A + hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A [strain (RGSB)] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis A vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis A - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hepatitis A, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Hepatitis A - Pipeline by Biological E Ltd, H2 2020
Hepatitis A - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
Hepatitis A - Pipeline by Cadila Healthcare Ltd, H2 2020
Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, H2 2020
Hepatitis A - Pipeline by Etna Biotech Srl, H2 2020
Hepatitis A - Pipeline by Indian Immunologicals Ltd, H2 2020
Hepatitis A - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H2 2020
Hepatitis A - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020
Hepatitis A - Pipeline by Sinovac Biotech Ltd, H2 2020
Hepatitis A - Dormant Projects, H2 2020
Number of Products under Development for Hepatitis A, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Hepatitis A - Pipeline by Biological E Ltd, H2 2020
Hepatitis A - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
Hepatitis A - Pipeline by Cadila Healthcare Ltd, H2 2020
Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, H2 2020
Hepatitis A - Pipeline by Etna Biotech Srl, H2 2020
Hepatitis A - Pipeline by Indian Immunologicals Ltd, H2 2020
Hepatitis A - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H2 2020
Hepatitis A - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2020
Hepatitis A - Pipeline by Sinovac Biotech Ltd, H2 2020
Hepatitis A - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Hepatitis A, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development for Hepatitis A, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
